Addendum to the clipping:
Germaine to the above circle of discoveries, and in order to precisely hit a fast moving target such as cancer, is the recognition that (despite or due to the bigPharma capitalistic mission) advances marches on, beyond the role of chemoradiotherapies of the 80’s, to the role of precision molecular oncology in the shadow of multidisciplinary approaches. Quotations from Dr Lundberg picked out from the 15 pearls of deep sight, additionally highlight on this clipping the need , especially in surgical pathology /hematopathology, to address issues in patient safety and quality of care by improving visualization diagnostics into more precise data analytics diagnosticcs as an horizon guidepost to patient trust by promoting transparency, innumeracy and objectivity in morphoimmunobiomarker-based diagnosis. We at IHCFLOW, like to lead the footpaths and shoot for the guideposts into the future> I quote:
” 6.The concomitant relative rise of cancer to top killer, and the birth and early promise of precision molecular oncology
7.The birth, development, and opportunities of the patient safety movement as the ultimate marker of quality of care.”
reference: Achievements (Some Dubious) in Medicine: The Past 20 Years
George D. Lundberg, MD
Medscape: July 20, 2015
Addendum to the clipping:
Germaine to the above circle of discoveries, and in order to precisely hit a fast moving target such as cancer, is the recognition that (despite or due to the bigPharma capitalistic mission) advances marches on, beyond the role of chemoradiotherapies of the 80’s, to the role of precision molecular oncology in the shadow of multidisciplinary approaches. Quotations from Dr Lundberg picked out from the 15 pearls of deep sight, additionally highlight on this clipping the need , especially in surgical pathology /hematopathology, to address issues in patient safety and quality of care by improving visualization diagnostics into more precise data analytics diagnosticcs as an horizon guidepost to patient trust by promoting transparency, innumeracy and objectivity in morphoimmunobiomarker-based diagnosis. We at IHCFLOW, like to lead the footpaths and shoot for the guideposts into the future> I quote:
” 6.The concomitant relative rise of cancer to top killer, and the birth and early promise of precision molecular oncology
7.The birth, development, and opportunities of the patient safety movement as the ultimate marker of quality of care.”
reference: Achievements (Some Dubious) in Medicine: The Past 20 Years
George D. Lundberg, MD
Medscape: July 20, 2015
Hernani Cualing